Corticosteroids as Additive in Temporomandibular Joint (TMJ) Arthrocentesis
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
The aim is to compare the effectiveness of corticosteroid administration (dexamethasone) with a placebo (saline), following arthrocentesis of for the temporomandibular joint (TMJ). Twenty-eight participants with TMJ arthralgia, mainly related to osteoarthritis ae randomly assigned to two arms of a parallel double blind RCT. In both arms an arthrocentesis procedure is carried out, while a single dose intraarticular dexamethasone was delivered to participants in one arm. Saline was delivered in the other arm to serve as a control. Follow up visits were scheduled after 1, 3 and 24 weeks. During each visit TMJ pain (on a 100mm VAS) and joint stiffness (mouth opening in mm) are scored. Generalized estimating equations (GEE) are used for statistical analysis.
Condition | Intervention | Phase |
---|---|---|
Arthritis |
Drug: Dexamethasone Drug: Isotonic saline |
Phase 4 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
Official Title: | Corticosteroids as Additive in Arthrocentesis of the Temporomandibular Joint: Double Blind, Randomised Controlled Trial of Effectiveness. |
- Change from Baseline in TMJ pain at 24 weeks [ Time Frame: 0 (T0), and at 1 (T1), 3 (T2) and 24 (T3) weeks. ] [ Designated as safety issue: No ]Change over 24 weeks from baseline for TMJ pain at rest and during mandibular movements. Measured by a 100 mm Visual Analogue Scale (VAS), limited by "no pain" and "worst pain imaginable".
- Change from Baseline in Maximal interincisal opening at 24 weeks [ Time Frame: T0, and at T1, T2 and T3. ] [ Designated as safety issue: No ]Change over 24 weeks from baseline maximal interincisal opening at rest and during mandibular movements . Measured in mm between the incisal edges of the center incisors.
- Change from baseline of mandibular function impairment at 24 weeks. [ Time Frame: T0, T1, T2 and T3 ] [ Designated as safety issue: No ]Change over 24 weeks from baseline for the MFIQ. The MFIQ is a questionnaire assessing, on a five point scale, discomfort while performing mandibular functions and during eating of food with different consistencies (range of 0 - 68).
Enrollment: | 28 |
Study Start Date: | December 2008 |
Estimated Study Completion Date: | December 2010 |
Estimated Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Placebo Comparator: Placebo |
Drug: Isotonic saline
1 ml of isotonic saline was applied once, following the arthrocentesis procedure of the TMJ
Other Name: Isotonic Saline
|
Experimental: Dexamethasone |
Drug: Dexamethasone
1 ml of 20mg/ml solution was applied once, following the arthrocentesis procedure of the TMJ
Other Name: Dexamethasone
|
Detailed Description:
The arthrocentesis procedure was performed under local anaesthesia and took place in a closed operation room under controlled conditions. After marking the points for insertion of the needles, a first 18 gauge injection needle was inserted into the upper intra-articular space of the TMJ. Correct positioning of the needle was determined by injecting and aspirating saline. Subsequently, a second 18 gauge needle was inserted into the upper joint space about 8-10 mm anterior of the first needle. Correct positioning of the second needle was confirmed by allowing injected saline to leave the joint through the first needle. After positioning of the needles, one needle was connected to a medical infusion system to passively allow isotonic saline of 37 degrees Celsius to enter the upper joint compartment. The other needle was connected to an outflow tube to allow the fluid to exit the joint. In about 15 minutes, approximately 300 ml saline passively flushed the joint. Thereafter, the inflow was stopped and the prepared syringe (see randomisation procedure) that contained either dexamethasone or saline was connected to the inflow needle. In this way, either 1 cc of dexamethasone or an equal amount of saline was washed through the joint in a blinded way. At the end of the procedure, the needles were removed from the joint, and after hemostasis by compression (if necessary) the skin overlying the TMJ was covered with a sterile band aid.
All patients were then instructed to avoid TMJ loading by following a soft diet for at least two weeks, then gradually advancing to more tough food. In addition, ibuprofen 600 mg 3dd was prescribed for the first 2-5 days to reduce any postoperative pain. All procedures were performed by one surgeon.
Follow up visits were scheduled after 1 (T1), 3 (T2) and 24 (T3) weeks.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Pain localized in one of the TMJs (TMJ arthralgia).
Exclusion Criteria:
- No significant relief of pain within 10 minutes after anaesthesia (injecting 0,1 ml articaine 40 mg/ml) of the TMJ
- Past history of open surgery in the affected joint
- Known polyarthritis (mostly rheumatoid arthritis)
- Age under 18 yrs
- Ankylosis of the TMJ
- Reported pregnancy
Netherlands | |
University Medical Centre Groningen | |
Groningen, Netherlands, 9700 RB |
Principal Investigator: | James Huddleston Slater, PhD | University Medical Center |
No publications provided
Responsible Party: | JJR Huddleston Slater, University Medical Center Groningen |
ClinicalTrials.gov Identifier: | NCT01275014 History of Changes |
Other Study ID Numbers: | UMCG_KCHIR_01, 14439 |
Study First Received: | November 29, 2010 |
Last Updated: | January 11, 2011 |
Health Authority: | Netherlands: Medical Ethics Review Committee (METC) Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
Keywords provided by University Medical Centre Groningen:
TMJ corticosteroids osteoarthritis arthrocentesis pain |
Additional relevant MeSH terms:
Arthritis Joint Diseases Musculoskeletal Diseases Dexamethasone acetate Dexamethasone Dexamethasone 21-phosphate BB 1101 Anti-Inflammatory Agents Therapeutic Uses Pharmacologic Actions Antiemetics Autonomic Agents |
Peripheral Nervous System Agents Physiological Effects of Drugs Central Nervous System Agents Gastrointestinal Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal Antineoplastic Agents Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on October 18, 2012